Clinical Trials Directory

Trials / Conditions / Metastatic Renal Cancer

Metastatic Renal Cancer

12 registered clinical trials studyying Metastatic Renal Cancer — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingLu-177 PSMA Treatment in Cell Renal Carcinoma
NCT06959433
Ankara UniversityPhase 3
RecruitingA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
NCT07123090
Stephanie BergPhase 2
RecruitingSABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
NCT06583070
Peking University First Hospital—
RecruitingMeasuring Oncological Value of Exercise and Statin
NCT05796973
Tampere University HospitalPhase 3
CompletedKetogenic Diet for Patients Receiving Treatment for Metastatic Renal Cell Carcinoma
NCT04316520
University Hospital, AngersN/A
UnknownSafety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
NCT03630692
Institut Cancerologie de l'Ouest—
TerminatedEverolimus Modulation of Anti-tumor T CD4 Immune Responses
NCT02837757
Centre Hospitalier Universitaire de BesanconN/A
TerminatedPRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
NCT02479490
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSPhase 2
CompletedPerfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Ca
NCT02086734
Ludwig-Maximilians - University of Munich—
TerminatedModified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Met
NCT01457131
National Cancer Institute (NCI)Phase 1
TerminatedMAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCT01273181
National Cancer Institute (NCI)Phase 1 / Phase 2
TerminatedPhase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic M
NCT01160445
National Cancer Institute (NCI)Phase 2